Research on Pancreatic Cancer Classification and Drug Precision Treatment Based on Drug Matching Features

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000038624

Enrollment

Unknown

Registered

2020-09-26

Start date

2020-10-01

Completion date

Unknown

Last updated

2020-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic cancer

Interventions

Case series:Drug precision treatment

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) No serious underlying disease; (2) Pathologically diagnosed as pancreatic cancer; (3) No significant heart, lung, or kidney dysfunction, and no HIV or syphilis infection; (4) All patients should sign informed consent when enrolled.

Exclusion criteria

Exclusion criteria: (1) Unstable angina pectoris, symptomatic congestive heart failure, severe arrhythmia, myocardial infarction in the past 6 months, prolonged QT interval (> 450ms); (2) Other organs occurred malignant tumor within the last 5 years; (3) The patient cannot be followed up or is participating in other clinical trials.

Design outcomes

Primary

Measure	Time frame
The effect of candidate drugs in in vitro models;	—

Countries

China

Contacts

Public ContactBin Song

Shanghai Changhai Hospital

smmusb@126.com+86 13917022140

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026